ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.
Understanding drug-resistant gonorrhoea: an ECDC whole genome sequencing study
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens? The first study of this kind within an international surveillance programme for sexually transmitted infections shows distribution of drug-resistant gonorrhoea strains across Europe.
ECDC-EMCDDA review: Can active case finding help reduce communicable diseases in prisons?
ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) have systematically retrieved and assessed evidence on active case findings for blood-borne viruses like HIV, hepatitis B and C, sexually transmitted infections as well as tuberculosis in prison settings in the EU/EEA.
31st Congress of IUSTI-Europe on Sexually Transmitted Infections
The 31st IUSTI (International Union Against Sexually Transmitted Infections) Europe Congress will address the broad range of science and clinical practice in the field of sexually transmitted infections.
WorldPride Madrid, June 2017, ECDC rapid risk assessment
ECDC has published a rapid risk assessment to assess the risk of outbreaks and transmission of communicable diseases during the WorldPride festival period taking place in Madrid in June 2017. For respiratory and vector-borne diseases, the risk is considered low, for food and waterborne diseases the risk is low to moderate, for vaccine-preventable diseases, it is moderate and for sexually transmitted infections, the risk is moderate to high.
Encouraging decrease in certain antibiotic resistance levels of gonococci across Europe
In 2014, the susceptibility of gonococci to two of the recommended antibiotics for gonorrhoea treatment has shown signs of improvement, according to results from the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP). At the same time, a significant increase in resistance to another antibiotic agent that is part of the suggested dual therapy of gonorrhoea was observed.
Pre-exposure prophylaxis in the EU/EEA setting: challenges and opportunities
Although clinical trials and other studies have demonstrated the efficacy and effectiveness of pre-exposure prophylaxis (PrEP) for HIV and existing guidelines have recommended making PrEP available within combination HIV prevention packages, there is not yet clear consensus in Europe with regard to whether and how to implement PrEP.